Trials
6 active
8 in total · 5 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Administered as two separate SC injections. Treatment duration of up to 52 weeks of navepegritide and placebo for lonapegsomatropin followed by 52 weeks of navepegritide and lonapegsomatropin.”In the company’s words, NCT07924059 on ClinicalTrials.gov
- Tested for
- Achondroplasia (5 trials), Hypochondroplasia
- Main trialPhase 3
- “This pivotal trial is being conducted to evaluate the efficacy, safety and tolerability of dual therapy with navepegritide and lonapegsomatropin administered as separate subcutaneous (SC) injections once weekly in children with achondroplasia (ACH) aged 2 to 17 years.”In the company’s words, NCT07924059 on ClinicalTrials.gov
- Other names
- TransCon CNP
Other drugs for Achondroplasia
- VosoritideBioMarin Pharmaceutical · Phase 3
- LonapegsomatropinAscendis Pharma Endocrinology Division A/S · Phase 3
- KK8398Kyowa Kirin Co., Ltd. · Phase 3
- BMN 333BioMarin Pharmaceutical · Phase 2/3
- ABSK061Abbisko Therapeutics Co, Ltd · Phase 1/2
- DabogratinibTyra Biosciences, Inc · Phase 2
Coming up5
- Sep 2027Phase 2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- Sep 2028Phase 3 trial completes · ClinicalTrials.gov
- Oct 2028Phase 3 trial completes · ClinicalTrials.gov
- Jan 2039Phase 2/3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 12 NovEU CHMP positive opinion, per Ascendis Pharma A/S SEC 6-K: Navepegritide · SEC
- 9 NovNew trial: none to Phase 3 · ClinicalTrials.gov NCT07924059
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Sep 2028 | Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia | |
| Phase 3Not yet recruiting | Oct 2028 | A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide Versus Placebo in Children and Adolescents With Hypochondroplasia | |
| Phase 2/3Enrolling by invitation | Jan 2039 | A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia | |
| Phase 2Active, not recruiting | 14 Nov 2025 | A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia | |
| Phase 2Active, not recruiting | Sep 2027 | A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia. | |
| Phase 2Recruiting | Dec 2027 | A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia | |
| Phase 2/3Completed | 9 Aug 2024 | A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia | |
| Phase 2Completed | 27 Sep 2022 | A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026